MQ
Scholar Rock Holding Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Apitegromab | Spinal Muscular Atrophy (Types 2 & 3) | Phase 3 |
| SRK-181 | Solid Tumors (Immune Checkpoint Inhibitor Resistant) | Phase 1 |
| SRK-439 | Obesity / Muscle Attenuation | Preclinical |
| SRK-441 | Fibrotic Diseases | Discovery |
| Undisclosed Program | Anemia | Discovery |
Leadership Team at Scholar Rock Holding
JB
Jay Backstrom
President and Chief Executive Officer
DH
David Hallal
Chairman of the Board
YC
Yung Chyung
Chief Medical Officer
TM
Ted Myles
Chief Financial Officer and Head of Business Operations
ML
Matthew Larson
Senior Director, Talent Acquisition